Hernexeos and what’s next, with Vicky Brown

It’s been an exciting time recently for Boehringer Ingelheim oncology as the company recently received FDA approval for Hernexeos (zongertinib) just 44 days after submission under the FDA’s new Priority Voucher programme.

At Reuters Pharma USA this week, Boehringer's head of oncology and emerging areas, Vicky Brown, stopped to talk to pharmaphorum editor-in-chief Jonah Comstock about what the Hernexeos approval means for patients and what’s next for the company in launching the therapy.

Brown also discusses the importance of biomarker testing and what pharma companies need to do to support that testing when they have a novel targeted therapy. She also touches on some of the other areas where Boehringer is in early pipeline stages, including retinal health, inflammation, and mental health.

Check out the video to hear from a hot oncology company on the heels of some big news.